[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barbara Malene Fischer\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":74},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637413","phase-2-befast-study-68gaga-fapi-total-body-petct-for-better-and-faster-imaging-in-cancer-100637413",false,"NCT07629609","BEFAST Study, [68Ga]Ga-FAPI Total Body PET\u002FCT for Better and Faster Imaging in Cancer","[68Ga]Ga-FAPI Total Body PET\u002FCT for Improving Diagnostic Sensitivity and Preoperative Staging in Gastroesophageal Cancer and Pancreatic Cancer","BEFAST","Inclusion criteria for group A\n\n1. Male or female, over 18 years old\n2. Patients with suspected pancreatic cancer based on morphological findings on standard imaging\n3. CT or MRI or \\[18F\\]FDG PET\u002FCT evaluated on MDT with no initial sign of distant metastases\n4. Subjects must have been considered suitable for curative surgery at the time of the referral\n5. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B1\n\n1. Male or female over 18 years old\n2. Histological verified carcinoma from the lower esophagus, GEJ, or stomach\n3. Subjects must be considered operable and resectable at the time of referral for MDT\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nInclusion criteria for group B2\n\n1. Male or female over 18 years old\n2. Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach\n3. Subjects with localized disease assigned to perioperative chemotherapy or subjects with metastatic disease assigned to palliative systemic treatment.\n4. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nExclusion Criteria:\n\n1. Pregnancy or lactation\n2. Weight more than the maximum limit of a PET\u002FCT-scanner bed (140 kg)\n3. History of allergic reaction due to compounds similar to the chemical composition of \\[68Ga\\]Ga-FAPI-46","ALL","18 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer. The investigators hope that \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT can improve staging and treatment evaluation for these patient groups.\n\nThe main questions the trial aims to answer are:\n\n* Is \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT better at diagnosing metastatic disease in the abdomen compared other imaging modalities?\n* Can \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT produce accurate images in less than 30 min?\n\nResearchers will examine three different patient groups:\n\nGroup A) patients with pancreatic cancer, who are referred to surgery. Group B1) patients with gastroesophageal cancer, who are referred to diagnostic surgery (laparoscopy).\n\nGroup B2) a subgroup of gastroesophageal cancer patients, with a specific subtype cancer (signet ring cell carcinoma or poorly cohesive carcinoma), who are referred to oncological treatment.\n\nParticipants will undergo:\n\n* One \\[68Ga\\]Ga-FAPI Total Body PET\u002FCT before surgery (Group A), or before laparoscopy (group B1), or before oncological treatment (Group B2).\n* Participants in group B2 will also undergo a second \\[68Ga\\]Ga-FAPI-46 Total Body PET\u002FCT during treatment with chemotherapy.\n* All participants will fill out one questionnaire.\n* Researchers will follow the patients after the scans for 1 year.",[27,28],"Pancreatic Cancer, Adult","Gastroesophageal Cancer (GC)",[30,31,32,33,34],"PET\u002FCT","FAPI","pancreatic cancer","gastroesophageal cancer","signet ring cell carcinoma","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-05","ACTUAL",{"date":41,"type":39},"2024-01-16",{"date":43,"type":21},"2027-01",{"name":45,"class":46},"Barbara Malene Fischer","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":15,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100609484","phase-2-68gaga-fapi-total-body-petct-for-better-and-faster-imaging-in-cancer-100609484","NCT07215182","[68Ga]Ga-FAPI Total Body PET\u002FCT for Better and Faster Imaging in Cancer","[68Ga]Ga-FAPI PET\u002FCT for Response Evaluation During Immune Checkpoint Inhibitor Therapy in Malignant Melanoma","Inclusion Criteria:\n\n1. Male or female, \\>\u002F=18 years old\n2. Histological verified metastatic or locally advanced malignant melanoma\n3. Visible malignant lesions on \\[18F\\]FDG PET\u002FCT or CT\n4. Subjects must be considered inoperable\n5. Subjects must be considered medically suitable for ICT\n6. Subjects must be able to read and understand the patient information in Danish to give informed consent\n\nExclusion Criteria:\n\n1. Ocular or mucosal melanoma\n2. Other concurrent cancer disease\n3. Previous systemic oncological treatment with ICT\n4. Pregnancy or lactation\n5. Weight more than the maximum limit of a PET\u002FCT-scanner bed (140 kg)\n6. History of allergic reaction due to compounds similar to the chemical composition of \\[68Ga\\]Ga-FAPI- 46",{"count":56,"type":21},20,[24],"The goal of this clinical trial is to investigate the use of the tracer \\[68Ga\\]Ga-FAPI-46 for PET\u002FCT-imaging in response evaluation of patients with advanced stage malignant melanoma treated with immune checkpoint inhibitor therapy (ICT). The main question it aims to answer is:\n\n• Can \\[68Ga\\]Ga-FAPI-46 PET\u002FCT improve response evaluation in patients suffering from advanced stage malignant melanoma treated with ICT and potentially serve as a biomarker.\n\nResearchers will compare findings on the experimental \\[68Ga\\]Ga-FAPI-46 PET\u002FCT with findings on standard imaging (\\[18F\\]FDG PET\u002FCT).\n\nParticipants will undergo:\n\n* Two \\[68Ga\\]Ga-FAPI-46 PET\u002FCT scans: one before treatment initiation with ICT and one after three months.\n* Two blood samples\n* Passive follow-up 6 months after the last scan \\[68Ga\\]Ga-FAPI-46 PET\u002FCT",[60],"Malignant Melanoma Stage IV",[62,63,64,65],"FAPI PET\u002FCT","Immune checkpoint inhibitor therapy","malignant melanoma","response evaluation","2025-10-02",{"date":68,"type":39},"2025-10-10",{"date":70,"type":39},"2025-08-15",{"date":72,"type":21},"2027-02-20",{"name":45,"class":46},""]